ÇÁ·Î±×·¥
½Ã°£ | °Á | |
---|---|---|
08:40~ | µî·Ï | |
08:50~09:00 | Àλ縻 | ȸÀå : ±èÁ¾Çö |
I. ÃֽŠ°¡À̵å¶óÀÎ ¸®ºä | ÁÂÀå: ÀÌÈÀÇ´ë ±è°æÈ¿ | |
09:00~09:35 | ¹«Áõ»ó ¼¼±Õ´¢ÀÇ ÀûÀýÇÑ Ä¡·á (IDSA guideline À§ÁÖ·Î) Management of asymptomatic bacteriuria |
Â÷ÀÇ´ë ÀÌÅÃÁø |
9:35~10:10 | ½Å»ý¾Æ Á¶¹ß¼º ÆÐÇ÷ÁõÀÇ ÀûÀýÇÑ Ä¡·á (AAP guidelineÀ§ÁÖ·Î) Management of neonatal early-onset sepsis |
ºÎ»êÀÇ´ë ¹Ú¼öÀº |
10:10~10:45 | ¿Ü·¡¿¡¼ ÁÖ»ç Ç×»ýÁ¦ÀÇ ÀûÀýÇÑ »ç¿ë (IDSA guideline À§ÁÖ·Î) Management of outpatient parenteral antimicrobial therapy |
ÇÑÀϺ´¿ø ÀÌÁø |
10:45~11:05 | Q&A | |
II. ¹é½ÅÀ¸·Î ¿¹¹æ °¡´ÉÇÑ Áúȯ | ÁÂÀå: °¡Å縯ÀÇ´ë ±èÁ¾Çö | |
11:05~11:45 | MMR ¹é½Å(È«¿ª°ú dzÁø Áß½ÉÀ¸·Î) MMR vaccine (focused on measles and rubella) |
Ãæ³²ÀÇ´ë Á¶Àº¿µ |
11:45~12:25 | ¹éÀÏÇØ ¹é½Å Pertussis vaccine |
¼¿ïÀÇ´ë ÃÖÀºÈ |
12:25~13:30 | Á¡½É½Ã°£ | |
III. °¨¿°°ü¸® "To screen or Not to screen?" (* Çʼö°ú¸ñ) | ÁÂÀå : ¼¿ïÀÇ´ë ÃÖÀºÈ | |
13:30~14:05 | Debate on Active surveillance for CRE/CPE | ÇѸ²ÀÇ´ë ÃÖ¼öÇÑ |
14:05~14:40 | Debate on Active surveillance for MRSA/VRE | °¡Å縯ÀÇ´ë ±è±âȯ |
14:40~15:15 | Practical approaches to Clostridioides difficile prevention in neonate and children | ÀüºÏÀÇ´ë Á¶´ë¼± |
15:15~15:35 | Q&A | |
IV. ÃֽŠ³í¹® ¸®ºä | ÁøÇà: ±³À°¿¬¼öÀÌ»ç | |
15:35~16:15 | ÃֽŠ¹é½Å °ü·Ã ³í¹® ¸®ºä (ÀÎÇ÷翣ÀÚ ¹é½Å À§ÁÖ·Î) | °¡Å縯ÀÇ´ë °Çö¹Ì |
16:15~16:25 | Çмú³í¹®»ó ¼ö¿©/ 2019 ºÐ°úÀü¹®ÀÇ ÀÚ°ÝÁõ ¼ö¿© | ȸÀå: ±èÁ¾Çö |
16:25~16:35 | Æóȸ»ç | ºÎȸÀå: ÃÖÀºÈ |